SCHEMBL20189409

SCHEMBL20189409

Cc1cnc(NCC2CCNCC2(F)F)cn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.45
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
LRRK2 Q5S007 1/20 0.34
CHEK1 O14757 2/20 0.33
PAK1 Q13153 2/20 0.33
CHEK2 O96017 1/20 0.33
MAP4K1 Q92918 1/20 0.32
PAK2 Q13177 1/20 0.31
CYP2D6 P10635 2/20 0.31
KCNH2 Q12809 2/20 0.31
TLR9 Q9NR96 2/20 0.31
TLR8 Q9NR97 2/20 0.31
TLR7 Q9NYK1 2/20 0.31
CLK2 P49760 1/20 0.30
CLK3 P49761 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20189406 1.00 GRIN2B (0.45) GRIN2BJAK2JAK1DDB1CRBN
Trifluoroacetic Acid SCHEMBL20188684 0.89 GRIN2B (0.46) GRIN2BDDB1CRBNPAK1CYP2D6
SCHEMBL20189541 0.85 GRIN2B (0.41) GRIN2BJAK2JAK1LRRK2PAK1
SCHEMBL20189544 0.85 GRIN2B (0.41) GRIN2BJAK2JAK1LRRK2PAK1
SCHEMBL20202870 0.82 GRIN2B (0.38) GRIN2BJAK2JAK1LRRK2PAK1
SCHEMBL20202900 0.82 GRIN2B (0.45) GRIN2BLRRK2MAP4K1CYP2D6KCNH2
SCHEMBL20202906 0.82 CHEK1 (0.53) CHEK1CHEK2KCNH2CLK2
SCHEMBL20189880 0.82 PAK1 (0.38) GRIN2BJAK2JAK1PAK1
SCHEMBL20202905 0.82 CHEK1 (0.53) CHEK1CHEK2KCNH2CLK2
SCHEMBL20189883 0.82 PAK1 (0.38) GRIN2BJAK2JAK1PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3544610-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS Rugen Holdings (Cayman) Limited (KY) 2019-10-02 EP disclosed
WO-2018098128-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2018-05-31 WO disclosed
WO-2018098128-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2018-05-31 WO disclosed